Tandem Diabetes Care (Nasdaq:TNDM) shares slid slightly after hours today on first-quarter results that were mixed compared to the consensus forecast.
The San Diego-based automated insulin delivery technology developer posted losses of $14.7 million, or 23¢ per share, on sales of $175.9 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red despite sales growth of 24.7%.
Losses per share of 23¢ for Tandem came in 16¢ behind projections on Wall Street, where analysts were looking for sales of $168.43 million.
Get the full story at our sister site, Drug Delivery Business News.